Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 20,607 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Withdrawn Phase 4 Interventional

Velcade for Proliferative Lupus Nephritis

NCT01169857
View directory record Official record
Conditions
Lupus Nephritis, Proteinuria, Hematuria
Interventions
Velcade
Drug
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

NCT00101101
View directory record Official record
Conditions
Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis

NCT02794012
View directory record Official record
Conditions
Rheumatoid Arthritis, Periodontal Disease
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

NCT00002212
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Bexarotene
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Palm Springs, California • New Orleans, Louisiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00075881
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 21, 2026, 7:32 PM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

NCT02028819
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Dolutegravir Sodium Monohydrate, Ibalizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 21, 2026, 7:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

NCT04148430
View directory record Official record
Conditions
B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
Interventions
Anakinra
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Withdrawn Phase 2 Interventional

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

NCT03003728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803
Drug · Procedure · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 21, 2026, 7:32 PM EDT
Available No phase listed Expanded access

Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

NCT06802328
View directory record Official record
Conditions
Non-Active Secondary Progressive Multiple Sclerosis
Interventions
Foralumab TZLS-401 50 µg
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

NCT04571567
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
Saakshi Khattri
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 21, 2026, 7:32 PM EDT
Recruiting Phase 3 Interventional

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
34
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis

NCT06264336
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
treadmill training
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Enrolling by invitation Not applicable Interventional

G7 Freedom Constrained Vivacit-E Liners

NCT05587244
View directory record Official record
Conditions
Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures, Avascular Necrosis, Dislocation, Hip
Interventions
Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Not yet recruiting No phase listed Observational

Combating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study

NCT07723599
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Observation
Other
Lead sponsor
University of Washington
Other
Eligibility
50 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

NCT04956263
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions
YG1699, Dapagliflozin
Drug
Lead sponsor
Youngene Therapeutics Inc., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

NCT01067287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CT-011, Dendritic Cell Fusion Vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 4 Interventional

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Garadacimab
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Litchfield Park, Arizona • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Not listed No phase listed Observational

A Real Life Evaluation of the Performance of a Large Volume Nebulizer

NCT00632112
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2009 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning

NCT00588328
View directory record Official record
Conditions
Lung Cancer, Non-Hodgkin's Lymphoma
Interventions
PET/CT scan
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

ACTH Gel Therapy in Rheumatoid Arthritis

NCT02030028
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ACTHAR gel
Drug
Lead sponsor
Dana Ascherman
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828
View directory record Official record
Conditions
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions
Companion blood samples with procedure
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

NCT04603300
View directory record Official record
Conditions
Peanut Allergy
Interventions
INT301, Placebo
Drug
Lead sponsor
Intrommune Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Belleville, New Jersey • Riverdale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 21, 2026, 7:32 PM EDT